Thomas Mechtersheimer ("Tom") has formal education in electrical engineering and graduated in economics at Reutlingen University, Germany. Most of Tom's postgraduate education was in leadership. He is a graduate of the Australian Institute of Company Directors (AICD) and has finished the AICD's Chairman course.
Tom started in Research at the Fraunhofer Institute in Germany and held various roles in Start-ups. He then moved on to work for Fresenius Group for 18 years, most of it Asia-based. His various roles in the first 15 years included Finance (CFO for APAC), Sales and General Management (SVP for South East Asia). Tom was a key leader in building the integrated renal health company Fresenius Medical Care in Asia. During his last years with the Fresenius Group, Tom was appointed to the Management Board for Fresenius Kabi AG as its President for Asia Pacific with responsibility for around 1.3 billion USD in sales and ca. 4500 staff.
Tom co-founded Regeneus, a stem cell company now listed on the ASX as well as prostaCare, a company developing a novel DC ablation based BPH treatment. Today, he owns and leads the Passion Innovation Group and is the founder and executive chairman of neuroCare.
Tom has deep experience in starting up markets from scratch, building successful teams and global ventures. His profound track record and his passion for leadership enable him to unlock the potential of innovations.
Tom gives back via various engagements in NGOs and in education. He is married with 3 children and is a keen tennis player and car afficionado.